Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | ADH1B | P00325 | 1/20 | 0.33 |
| ▸ | ADH1C | P00326 | 1/20 | 0.33 |
| ▸ | ADH1A | P07327 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3827248 | 0.94 | CA12 (0.32) | CA12CA1CA2CA9ADH1B | |
| SCHEMBL270365 | 0.86 | — | — | |
| SCHEMBL3771352 | 0.85 | PIK3CD (0.31) | — | |
| SCHEMBL1750328 | 0.84 | — | — | |
| SCHEMBL9349275 | 0.84 | ALDH1A1 (0.33) | CA12CA1CA2CA9ADH1B | |
| SCHEMBL270446 | 0.82 | ADH1A (0.33) | ADH1CADH1A | |
| SCHEMBL11378707 | 0.80 | — | — | |
| SCHEMBL23502501 | 0.78 | CA12 (0.35) | CA12CA1CA2CA9TSHR | |
| SCHEMBL270910 | 0.78 | ADH1C (0.33) | CA12CA1CA9ADH1BADH1C | |
| SCHEMBL13806341 | 0.78 | ALDH1A1 (0.37) | CA12CA1CA2CA9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 855 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116836148-A | Method for co-production of organic bromide and hydrogen through photocatalysis | 中国科学院大连化学物理研究所 | 2023-10-03 | — | — | CN | claimed |
| CN-111518051-A | Aliphatic group substituted thiazolinone compound, preparation method, medicinal composition and application thereof | 中国科学技术大学 | 2020-08-11 | — | — | CN | claimed |
| CN-101896487-A | N-demethylation of N-methyl morphinans | MALLINCKRODT INC | 2010-11-24 | — | — | CN | claimed |
| EP-2222677-A1 | N-DEMETHYLATION OF N-METHYL MORPHINANS | Mallinckrodt Inc. (US) | 2010-09-01 | — | — | EP | claimed |
| US-7671204-B2 | N-demethylation of N-methyl morphinans | MALLINCKRODT INC. (US) | 2010-03-02 | — | — | US | claimed |
| WO-2009078990-A1 | N-DEMETHYLATION OF N-METHYL MORPHINANS | MALLINCKRODT INC. (US) | 2009-06-25 | — | — | WO | claimed |
| US-20090156815-A1 | N-demethylation of N-methyl morphinans | SpecGx LLC | 2009-06-18 | — | — | US | claimed |
| US-6380197-B1 | FOR TREATING AND PREVENTING A PLETHORA OF DISEASES INCLUDING DIABETES | AVENTIS PHARMA S. A. (FR) | 2002-04-30 | — | — | US | claimed |
| EP-0457195-B1 | Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO (JP) | 1998-04-15 | — | — | EP | claimed |
| US-5656604-A | HYPOTENSIVE AGENT; ENDOTHELIN ANTAGONIST | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-08-12 | — | — | US | claimed |
| US-5110808-A | Aldose reductase inhibitors; peripheral effects of diabetes and galactosemia | IMPERIAL CHEMICAL INDUSTRIES, PLC (GB) | 1992-05-05 | — | — | US | claimed |
| EP-0469889-A1 | (p-Carbonylaminophenyl)-sulphonyl-nitromethane derivatives | ZENECA LIMITED (GB) | 1992-02-05 | — | — | EP | claimed |
| EP-0457195-A2 | Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-11-21 | — | — | EP | claimed |
| EP-0230224-B1 | PROCESS FOR THE PREPARATION OF ALCOXYCARBONYL ISOCYANATES | BAYER AG (DE) | 1991-07-17 | — | — | EP | claimed |
| EP-0334014-A2 | Substitued imidazolinones and imidazolethiones | BAYER AG (DE) | 1989-09-27 | — | — | EP | claimed |
| EP-0287890-A1 | Substituted pyrroles | BAYER AG (DE) | 1988-10-26 | — | — | EP | claimed |
| US-4777283-A | Process for the preparation of alkoxycarbonyl isocyanates | BAYER AKTIENGESELLSCHAFT (DE) | 1988-10-11 | — | — | US | claimed |
| US-4695412-A | Preparation of acyloxybenzenesulfonic acids and their alkali metal and alkaline earth metal salts | BASF AKTIENGESELLSCHAFT (DE) | 1987-09-22 | — | — | US | claimed |
| EP-0031504-B1 | PROCESS FOR THE PREPARATION OF CARBOXYLIC ACID CHLORIDES | BASF Aktiengesellschaft (DE) | 1982-12-15 | — | — | EP | claimed |
| EP-0031504-A1 | Process for the preparation of carboxylic acid chlorides | BASF Aktiengesellschaft (DE) | 1981-07-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156815-A1 | N-demethylation of N-methyl morphinans | OPRM1, PNMT, OPRD1 | CA12 4213/4885CA1 3495/4885CA2 4054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.